Neuronetics, Inc. (STIM) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US64131A1051
Neuronetics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 149.16 m USD |
| Gross profit | 72.31 m USD |
| Operating income | -31.44 m USD |
| EBIT | -30.72 m USD |
| Net income | -39.00 m USD |
| Diluted EPS – continuing operations | -0.59 USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Neuronetics, Inc.
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
More stocks
- Lam Soon (Thailand) Public Company Limited (LST.BK)
- AMREP CORP. (AXR)
- AMPAK Technology Inc. (6546.TWO)
- Bank of South Carolina Corp (BKSC)
- Decisive Dividend Corp (DE.V)
- S-Tech Corp. (1584.TWO)
- University Bancorp Inc (UNIB)
- Daihan Pharmaceutical Co.Ltd (023910.KQ)
- Rafael Microelectronics (6568.TWO)
- Fortitude Gold Corp (FTCO)
- DMS Co.Ltd (068790.KQ)
- Vytrus Biotech S.A. (VYT.MC)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.